Lacritin, a novel human tear glycoprotein, promotes sustained basal tearing and is well tolerated
Lacritin is a novel human tear glycoprotein that promotes basal tear peroxidase secretion by rat lacrimal acinar cells in vitro. This study investigates whether lacritin is prosecretory when added topically to the ocular surface of normal living rabbits, and if so, what is its efficacy and tolerabil...
Saved in:
Published in | Investigative ophthalmology & visual science Vol. 52; no. 9; pp. 6265 - 6270 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Association for Research in Vision and Ophthalmology, Inc
05.08.2011
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Lacritin is a novel human tear glycoprotein that promotes basal tear peroxidase secretion by rat lacrimal acinar cells in vitro. This study investigates whether lacritin is prosecretory when added topically to the ocular surface of normal living rabbits, and if so, what is its efficacy and tolerability versus cyclosporine and artificial tears.
Purified recombinant human lacritin (1, 10, 50, or 100 μg/mL), inactive lacritin truncation mutant C-25 (10 μg/mL), cyclosporine (0.05%), or artificial tears were topically administered to eyes of normal New Zealand White rabbits either as a single dose or three times daily for 14 days with monitoring of basal tear production. Basal tearing under proparacaine anesthesia was repeatedly assessed throughout and 1 week after chronic treatment ceased. Eyes were examined weekly by slit-lamp biomicroscopy.
Lacritin acutely increased basal tearing to 30% over vehicle at 240 minutes. Three times daily treatment with 10-100 μg/mL lacritin was well tolerated. Basal tearing became progressively elevated 4, 7, and 14 days later and was 50% over baseline (50 μg/mL lacritin) 1 week after treatment had ceased. Cyclosporine elevated tearing to a similar level on days 4 and 7 but had little or no effect on day 14 and had returned to baseline 1 week after ending treatment. C-25 and artificial tears had no effect.
Lacritin acutely stimulates basal tear flow that is sustained for at least 240 minutes. Two weeks of lacritin treatment three times daily was well tolerated and progressively elevated the basal tear flow. One week after treatment ended, basal tearing was still 50% over baseline. In contrast, cyclosporine triggered mild to moderate corneal irritation and a temporary elevation in tearing. |
---|---|
AbstractList | Lacritin is a novel human tear glycoprotein that when added topically promotes tearing in normal New Zealand White rabbits. After a two-week treatment, lacritin stimulated basal tearing, and cyclosporine triggered mild to moderate corneal irritation and a temporary elevation in tearing. Lacritin is a novel human tear glycoprotein that promotes basal tear peroxidase secretion by rat lacrimal acinar cells in vitro. This study investigates whether lacritin is prosecretory when added topically to the ocular surface of normal living rabbits, and if so, what is its efficacy and tolerability versus cyclosporine and artificial tears. Purified recombinant human lacritin (1, 10, 50, or 100 μg/mL), inactive lacritin truncation mutant C-25 (10 μg/mL), cyclosporine (0.05%), or artificial tears were topically administered to eyes of normal New Zealand White rabbits either as a single dose or three times daily for 14 days with monitoring of basal tear production. Basal tearing under proparacaine anesthesia was repeatedly assessed throughout and 1 week after chronic treatment ceased. Eyes were examined weekly by slit-lamp biomicroscopy. Lacritin acutely increased basal tearing to 30% over vehicle at 240 minutes. Three times daily treatment with 10-100 μg/mL lacritin was well tolerated. Basal tearing became progressively elevated 4, 7, and 14 days later and was 50% over baseline (50 μg/mL lacritin) 1 week after treatment had ceased. Cyclosporine elevated tearing to a similar level on days 4 and 7 but had little or no effect on day 14 and had returned to baseline 1 week after ending treatment. C-25 and artificial tears had no effect. Lacritin acutely stimulates basal tear flow that is sustained for at least 240 minutes. Two weeks of lacritin treatment three times daily was well tolerated and progressively elevated the basal tear flow. One week after treatment ended, basal tearing was still 50% over baseline. In contrast, cyclosporine triggered mild to moderate corneal irritation and a temporary elevation in tearing. |
Author | Samudre, Sandeep Laurie, Gordon W Sheppard, Jr, John D Lattanzio, Jr, Frank A Hosseini, Alireza McKown, Robert L Williams, Patricia B Lossen, Victoria |
Author_xml | – sequence: 1 givenname: Sandeep surname: Samudre fullname: Samudre, Sandeep email: samudrss@evms.edu organization: Department of Physiological Sciences, Eastern Virginia Medical School, Norfolk, Virginia 23501, USA. samudrss@evms.edu – sequence: 2 givenname: Frank A surname: Lattanzio, Jr fullname: Lattanzio, Jr, Frank A – sequence: 3 givenname: Victoria surname: Lossen fullname: Lossen, Victoria – sequence: 4 givenname: Alireza surname: Hosseini fullname: Hosseini, Alireza – sequence: 5 givenname: John D surname: Sheppard, Jr fullname: Sheppard, Jr, John D – sequence: 6 givenname: Robert L surname: McKown fullname: McKown, Robert L – sequence: 7 givenname: Gordon W surname: Laurie fullname: Laurie, Gordon W – sequence: 8 givenname: Patricia B surname: Williams fullname: Williams, Patricia B |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/21087963$$D View this record in MEDLINE/PubMed |
BookMark | eNpVkMtOwzAQRS0Eog_YsUb-gKZ47NRxNkio4iVVYgPraJw4rVFqV3Za1L8noVCV1dyZOXNHuiNy7rwzhNwAmwLI7M76XZwCSyTn7IwMYTbjySxT4vxED8goxk_GOABnl2TAgaksl2JIcIFlsK11E4rU-Z1p6Gq7Rkdbg4Eum33pN8G3pgc6se5kpHEbW7TOVFRjxOaHtW5J0VXURvplmm7mGxOwNdUVuaixieb6t47Jx9Pj-_wlWbw9v84fFkkplGiTVGRVmpoa0hLqWSVyJbkCRGkYy1FJo3Slc65VmcsaKqG55sAzlmmmgGspxuT-4LvZ6rWpSuPagE2xCXaNYV94tMX_jbOrYul3hYBMMsg7g8nBoAw-xmDq4y2woo-66KPumz7qDr89_XeE_7IV35B1fro |
CitedBy_id | crossref_primary_10_1016_j_ajo_2020_01_029 crossref_primary_10_1016_j_drudis_2019_02_006 crossref_primary_10_1016_j_jprot_2020_103724 crossref_primary_10_1016_j_exer_2022_109121 crossref_primary_10_1021_acs_jproteome_5b00179 crossref_primary_10_1016_j_exer_2022_109101 crossref_primary_10_1016_j_jtos_2017_05_006 crossref_primary_10_5301_ejo_5000593 crossref_primary_10_1016_j_exer_2015_08_015 crossref_primary_10_1016_j_exer_2013_08_016 crossref_primary_10_1074_jbc_M112_422717 crossref_primary_10_1080_17469899_2023_2258279 crossref_primary_10_3390_molecules28020648 crossref_primary_10_1002_pmic_201800187 crossref_primary_10_1371_journal_pone_0063949 crossref_primary_10_1016_j_exer_2016_04_019 crossref_primary_10_1007_s00347_017_0608_6 crossref_primary_10_1016_j_jprot_2016_05_006 crossref_primary_10_3109_02713683_2013_859275 crossref_primary_10_1167_tvst_9_9_13 crossref_primary_10_1016_j_jconrel_2014_11_016 crossref_primary_10_1016_j_jtos_2017_03_006 crossref_primary_10_1371_journal_pone_0053018 crossref_primary_10_1016_j_exer_2022_109274 crossref_primary_10_1038_srep18362 crossref_primary_10_1074_jbc_RA120_015833 crossref_primary_10_1074_jbc_M114_570143 crossref_primary_10_1371_journal_pone_0051979 crossref_primary_10_1097_ICO_0000000000003091 crossref_primary_10_1016_j_jaci_2013_09_040 crossref_primary_10_1016_j_exer_2013_05_020 crossref_primary_10_1080_27694127_2023_2178996 crossref_primary_10_1016_j_celrep_2022_111307 crossref_primary_10_1016_j_exer_2019_04_022 crossref_primary_10_1177_1120672121998922 crossref_primary_10_1097_OPX_0000000000000664 crossref_primary_10_1097_ICL_0000000000000666 crossref_primary_10_3390_ijms21176157 crossref_primary_10_1016_j_jprot_2020_103881 |
ContentType | Journal Article |
Copyright | Copyright © Association for Research in Vision and Ophthalmology 2011 |
Copyright_xml | – notice: Copyright © Association for Research in Vision and Ophthalmology 2011 |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 5PM |
DOI | 10.1167/iovs.10-6220 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1552-5783 |
EndPage | 6270 |
ExternalDocumentID | 10_1167_iovs_10_6220 21087963 |
Genre | Journal Article Research Support, N.I.H., Extramural |
GrantInformation_xml | – fundername: NEI NIH HHS grantid: R01 EY018222 – fundername: NEI NIH HHS grantid: R01 EY018222-05 – fundername: NEI NIH HHS grantid: R01 EY013143-09 – fundername: NEI NIH HHS grantid: R42 EY015376-03S109 – fundername: NEI NIH HHS grantid: R42 EY015376 – fundername: NEI NIH HHS grantid: R01 EY013143 – fundername: PHS HHS grantid: R01 EYO18222 |
GroupedDBID | --- 18M 2WC 34G 39C 5GY 5RE ACGFO ACNCT ADBBV AENEX AFOSN ALMA_UNASSIGNED_HOLDINGS BAWUL CGR CS3 CUY CVF DIK DU5 E3Z EBS ECM EIF EJD F5P GROUPED_DOAJ GX1 N9A NPM OK1 P2P RHF RPM SJN TR2 TRV W8F WH7 WOQ WOW AAYXX CITATION 5PM |
ID | FETCH-LOGICAL-c383t-437d44ef14c1f5d3986281aa6e009a86e8bdb92b8c96f1d3b2b212707b0812b63 |
IEDL.DBID | RPM |
ISSN | 1552-5783 0146-0404 |
IngestDate | Tue Sep 17 21:09:11 EDT 2024 Fri Aug 23 02:13:43 EDT 2024 Sat Sep 28 07:58:56 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 9 |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c383t-437d44ef14c1f5d3986281aa6e009a86e8bdb92b8c96f1d3b2b212707b0812b63 |
Notes | Contributed equally to the work and therefore should be considered equivalent authors. |
OpenAccessLink | https://europepmc.org/articles/pmc3176019?pdf=render |
PMID | 21087963 |
PageCount | 6 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_3176019 crossref_primary_10_1167_iovs_10_6220 pubmed_primary_21087963 |
PublicationCentury | 2000 |
PublicationDate | 2011-Aug-05 |
PublicationDateYYYYMMDD | 2011-08-05 |
PublicationDate_xml | – month: 08 year: 2011 text: 2011-Aug-05 day: 05 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Investigative ophthalmology & visual science |
PublicationTitleAlternate | Invest Ophthalmol Vis Sci |
PublicationYear | 2011 |
Publisher | Association for Research in Vision and Ophthalmology, Inc |
Publisher_xml | – name: Association for Research in Vision and Ophthalmology, Inc |
References | 17412322 - Exp Eye Res. 2008 Mar;86(3):457-8 19218606 - Invest Ophthalmol Vis Sci. 2009 Jun;50(6):2736-41 15219877 - Prog Retin Eye Res. 2004 Jul;23(4):449-74 18840430 - Exp Eye Res. 2009 May;88(5):848-58 19376264 - Prog Retin Eye Res. 2009 May;28(3):155-77 15952728 - J Proteome Res. 2005 May-Jun;4(3):820-5 8306892 - Development. 1993 Dec;119(4):1343-57 15851556 - Invest Ophthalmol Vis Sci. 2005 May;46(5):1593-8 15684812 - J Ocul Pharmacol Ther. 2004 Dec;20(6):533-47 17215105 - Cell Signal. 2007 May;19(5):945-57 19705875 - J Proteome Res. 2009 Nov;8(11):4889-905 16488965 - Br J Ophthalmol. 2006 Mar;90(3):372-7 16923831 - J Cell Biol. 2006 Aug 28;174(5):689-700 15952718 - J Proteome Res. 2005 May-Jun;4(3):719-24 17508121 - Ocul Surf. 2007 Apr;5(2):179-93 20110357 - J Biol Chem. 2010 Mar 26;285(13):9410-9 18848318 - Am J Ophthalmol. 2009 Feb;147(2):206-213.e3 10525117 - J Pharmacol Exp Ther. 1999 Nov;291(2):920-3 18677231 - Optom Vis Sci. 2008 Aug;85(8):643-52 20375347 - Invest Ophthalmol Vis Sci. 2010 Sep;51(9):4395-406 12414997 - J Cell Sci. 2002 Dec 1;115(Pt 23):4517-31 16102833 - Ophthalmology. 2005 Oct;112(10):1790-4 17216084 - Ocul Surf. 2004 Apr;2(2):131-48 11419941 - J Mol Biol. 2001 Jun 29;310(1):127-39 444137 - Arch Ophthalmol. 1979 Jun;97(6):1082-5 11133853 - Invest Ophthalmol Vis Sci. 2001 Jan;42(1):96-100 16982797 - J Cell Biol. 2006 Sep 25;174(7):1097-106 19770725 - Cornea. 2009 Dec;28(10):1109-17 9690893 - Jpn J Ophthalmol. 1998 May-Jun;42(3):168-73 14962426 - Am J Ophthalmol. 2004 Feb;137(2):337-42 17850790 - Exp Eye Res. 2007 Nov;85(5):651-8 14644860 - Ann Rheum Dis. 2003 Dec;62(12):1204-7 12697417 - Exp Eye Res. 2003 May;76(5):521-42 15037586 - Invest Ophthalmol Vis Sci. 2004 Apr;45(4):1182-7 10328967 - Exp Eye Res. 1999 May;68(5):541-6 19741242 - Invest Ophthalmol Vis Sci. 2010 Feb;51(2):782-9 12888056 - Am J Ophthalmol. 2003 Aug;136(2):318-26 19693291 - Mol Vis. 2009;15:1553-72 10434857 - Br J Ophthalmol. 1999 Apr;83(4):390-5 17043506 - J Clin Rheumatol. 2004 Aug;10(4):169-77 16186338 - Invest Ophthalmol Vis Sci. 2005 Oct;46(10):3589-96 16901338 - Genome Biol. 2006;7(8):R72 20335617 - Invest Ophthalmol Vis Sci. 2010 Aug;51(8):3969-76 12658556 - Curr Eye Res. 2002 Oct;25(4):227-35 |
References_xml | |
SSID | ssj0021120 |
Score | 2.304917 |
Snippet | Lacritin is a novel human tear glycoprotein that promotes basal tear peroxidase secretion by rat lacrimal acinar cells in vitro. This study investigates... Lacritin is a novel human tear glycoprotein that when added topically promotes tearing in normal New Zealand White rabbits. After a two-week treatment,... |
SourceID | pubmedcentral crossref pubmed |
SourceType | Open Access Repository Aggregation Database Index Database |
StartPage | 6265 |
SubjectTerms | Administration, Topical Animals Cyclosporine - administration & dosage Cyclosporine - adverse effects Eye Proteins - administration & dosage Eye Proteins - adverse effects Glycoproteins - administration & dosage Glycoproteins - adverse effects Intraocular Pressure Lacrimal Apparatus - drug effects Lacrimal Apparatus - metabolism Ophthalmic Solutions Rabbits Recombinant Proteins - administration & dosage Recombinant Proteins - adverse effects Tears - secretion Time Factors Tonometry, Ocular |
Title | Lacritin, a novel human tear glycoprotein, promotes sustained basal tearing and is well tolerated |
URI | https://www.ncbi.nlm.nih.gov/pubmed/21087963 https://pubmed.ncbi.nlm.nih.gov/PMC3176019 |
Volume | 52 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3JTsMwELWAA-KC2CmbfIAboU3sejkCorRAKyRAcKvseCIqpQmiBYm_Z-wmFb1yTDJZNBll3rOfXwg5NSpLwCg_wygh4pnmkUYUGymdMUiEQUbh1w73B6L7wu_e2m9LpF2vhQmi_dSOLop8fFGM3oO28mOcNmudWPOxf409D3mEbi6TZclYTdErlhVXXoz4CYiwQnmtdheyOSq_J0hXI5EkreAC3FJSC7bQkuZ9aFEj-afpdDbIeoUW6eXsqTbJEhRbZLVfzYdvE_NgUu9KVJxTQwflN-Q0jMrTZyxgepv_pGUwYvABj0F4BxP6NFszBY5emQle3cdiA6OmcLQ3oa-Q474y927L4HbIS-fm-bobVT9NiFIkm9OIM-k4hyzmaZy1HdNIWVRsjABEU0YJUNZZnViVapHFjtnEepP3lrQIDhIr2C5ZKcoC9gkFxWIAkaWIoXhsnBHezctJnUGMd2ENclbnbfgx88YYBk4h5NCn2m_4VDfI3iyX86g68w0iF7I8D_Cm14tHsBaC-XX17g_-feYhWavHhVvtI7Iy_fyCYwQWU3uCkLp3fxLK6RcYr85a |
link.rule.ids | 230,315,733,786,790,891,27955,27956,53825,53827 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nb9NAEB2VVgIuUD5aAhT2UG44ie31evcIFW1Kk6gSKfQW7cdYjXDtiqSV4Nczu7Yjwg2OtsdferueebtvnwEOtSwS1NLPMOYY8ULxSFEVG0lVpJgITYzCrx2eTMXogn--zC63IOvWwgTRvjWLflVe96vFVdBW3lzbQacTG5xPjijnEY9Qg3uwQ_01yTqS3vKsuHVjpI9ARG2Ud3p3kQ8W9d2SCGskkmQYfICHMlci3UhK60y0qZL8I-0cP4av3QM3apPv_duV6dtff3k5_vMb7cKjthBlH5rDT2ALq6dwf9JOtT8DPdbWGx5V75lm0_oOSxYG_NmM-gY7KX_aOng8-IDzoOnDJfvSLMdCxz7qJV3dx1JuZLpy7HTJvmFJ--rSGzmjew4Xx59mR6Oo_R9DZInHriKe5o5zLGJu4yJzqSI2JGOtBVKhpqVAaZxRiZFWiSJ2qUmM948f5obqjsSIdA-2q7rCF8BQpjGiKCyVZzzWTgtvFOZyVWBMd0l78K4DZH7T2G7MA10R-dxj6Dc8hj3Yb0BaR3WQ9iDfgG8d4P20N48QKMFXuwXh5X-f-RYejGaT8Xx8Oj17BQ-74edh9hq2Vz9u8YDql5V5E1rrb9HE71I |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbGJk28AONaLpsf4I00TeL68jgG3QZrVYlNTLxUvhyLiiypaDeJ_XqOnaRaedxjkpObPjvnfPbnL4S819LnoGWYYRSQMK9YorCKTaTyBeRcI6MIa4fHE35ywb5eDi_v_Oorivatmfer8qpfzX9FbeXiyqadTiydjo8w5yGPUOnC-fQB2cE-m4uOqLdcK2sdGfFDkGA7ZZ3mnYt0Xt8skbQmPM8H0Qt4IIXixUZiWmejTaXkndQzekx-dg_dKE5-969Xpm9v__NzvNdbPSGP2oKUHjYhe2QLqqdkd9xOuT8j-kzbYHxUfaSaTuobKGkc-Kfn2EfocfnX1tHrIQRMo7YPlvR7sywLHP2kl3j1EIs5kurK0dMl_QEl7qvLYOgM7jm5GH05PzpJ2v8yJBb57CphhXCMgc-YzfzQFQpZkcy05oAFm5YcpHFG5UZaxX3mCpOb4CM_EAbrj9zw4gXZruoKXhEKssgAuLdYprFMO82DYZgTykOGdyl65EMHymzR2G_MIm3hYhZwDBsBxx552QC1jupg7RGxAeE6IPhqbx5BYKK_dgvE63ufeUB2p59Hs7PTybc35GE3Cj0YviXbqz_X8A7LmJXZjw32H2Qh8dI |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Lacritin%2C+a+novel+human+tear+glycoprotein%2C+promotes+sustained+basal+tearing+and+is+well+tolerated&rft.jtitle=Investigative+ophthalmology+%26+visual+science&rft.au=Samudre%2C+Sandeep&rft.au=Lattanzio%2C+Jr%2C+Frank+A&rft.au=Lossen%2C+Victoria&rft.au=Hosseini%2C+Alireza&rft.date=2011-08-05&rft.eissn=1552-5783&rft.volume=52&rft.issue=9&rft.spage=6265&rft_id=info:doi/10.1167%2Fiovs.10-6220&rft_id=info%3Apmid%2F21087963&rft.externalDocID=21087963 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1552-5783&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1552-5783&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1552-5783&client=summon |